The Sinusitis drugs in development market research report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sinusitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sinusitis and features dormant and discontinued products.

GlobalData tracks 49 drugs in development for Sinusitis by 44 companies/universities/institutes. The top development phase for Sinusitis is preclinical with 11 drugs in that stage. The Sinusitis pipeline has 49 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Sinusitis pipeline products market are: GSK, Lyra Therapeutics and Aodh Lifesciences.

The key targets in the Sinusitis pipeline products market include Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R), Thymic Stromal Lymphopoietin (TSLP), and Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1).

The key mechanisms of action in the Sinusitis pipeline product include Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist with eight drugs in Phase III. The Sinusitis pipeline products include eight routes of administration with the top ROA being Subcutaneous and seven key molecule types in the Sinusitis pipeline products market including Monoclonal Antibody, and Small Molecule.

Sinusitis overview

Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from a viral or bacterial infection or from an allergy. Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache, and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder such as HIV/AIDS or cystic fibrosis, and another allergic condition.

For a complete picture of Sinusitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.